Mesorectal radiotherapy for early stage rectal cancer:a novel target volume by Peters, Femke P. et al.
 
 
University of Birmingham
Mesorectal radiotherapy for early stage rectal
cancer
Peters, Femke P.; Teo, Mark T. W.; Appelt, Ane L. ; Bach, Simon; Baatrup, Gunnar; de Wilt,
Johannes H. W.; Kronborg, Camilla Jensenius; Garm Spindler, Karen-Lise; Marijnen, Corrie
A. M.; Sebag-Montefiore, David
DOI:
10.1016/j.ctro.2020.02.001
License:
Creative Commons: Attribution-NonCommercial-NoDerivs (CC BY-NC-ND)
Document Version
Publisher's PDF, also known as Version of record
Citation for published version (Harvard):
Peters, FP, Teo, MTW, Appelt, AL, Bach, S, Baatrup, G, de Wilt, JHW, Kronborg, CJ, Garm Spindler, K-L,
Marijnen, CAM & Sebag-Montefiore, D 2020, 'Mesorectal radiotherapy for early stage rectal cancer: a novel
target volume', Clinical and Translational Radiation Oncology, vol. 21, pp. 104-111.
https://doi.org/10.1016/j.ctro.2020.02.001
Link to publication on Research at Birmingham portal
General rights
Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the
copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes
permitted by law.
•	Users may freely distribute the URL that is used to identify this publication.
•	Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private
study or non-commercial research.
•	User may use extracts from the document in line with the concept of ‘fair dealing’ under the Copyright, Designs and Patents Act 1988 (?)
•	Users may not further distribute the material nor use it for the purposes of commercial gain.
Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.
When citing, please reference the published version.
Take down policy
While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been
uploaded in error or has been deemed to be commercially or otherwise sensitive.
If you believe that this is the case for this document, please contact UBIRA@lists.bham.ac.uk providing details and we will remove access to
the work immediately and investigate.
Download date: 14. Jun. 2020
Clinical and Translational Radiation Oncology 21 (2020) 104–111Contents lists available at ScienceDirect
Clinical and Translational Radiation Oncology
journal homepage: www.elsevier .com/locate /c t roOriginal Research ArticleMesorectal radiotherapy for early stage rectal cancer: A novel target
volumehttps://doi.org/10.1016/j.ctro.2020.02.001
2405-6308/ 2020 The Author(s). Published by Elsevier B.V. on behalf of European Society for Radiotherapy and Oncology.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Abbreviations: OP, organ preservation; WG, working group; RO, radiation
oncologist.
⇑ Corresponding author at: Department of Radiotherapy, Netherlands Cancer
Institute, Postbus 90203, 1006 BE Amsterdam, the Netherlands.
E-mail addresses: f.peters@nki.nl (F.P. Peters), M.T.W.Teo@leeds.ac.uk (M.T.W.
Teo), A.L.Appelt@leeds.ac.uk (A.L. Appelt), S.P.Bach@bham.ac.uk (S. Bach), Gunnar.
Baatrup@rsyd.dk (G. Baatrup), Hans.deWilt@radboudumc.nl (J.H.W. de Wilt), cam.
kro@auh.rm.dk (C. Jensenius Kronborg), K.G.Spindler@rm.dk (K.-L. Garm Spindler),
c.marijnen@nki.nl (C.A.M. Marijnen), D.SebagMontefiore@leeds.ac.uk (D. Sebag-
Montefiore).
1 Present address: Department of Radiotherapy, Netherlands Cancer Institute,
Postbus 90203, 1006 BE Amsterdam, the Netherlands.Femke P. Peters a,⇑, Mark T.W. Teo b, Ane L. Appelt c, Simon Bach d, Gunnar Baatrup e,
Johannes H.W. de Wilt f, Camilla Jensenius Kronborg g, Karen-Lise Garm Spindler g,
Corrie A.M. Marijnen a,1, David Sebag-Montefiore c
aDepartment of Radiotherapy, Leiden University Medical Center, Postbus 9600, 2300 RC Leiden, the Netherlands
b Leeds Cancer Centre, St James’s University Hospital, Beckett Street, Leeds LS9 7TF, UK
c Leeds Institute of Medical Research at St James’s, University of Leeds and Leeds Cancer Centre, St James’s University Hospital, Beckett Street, Leeds LS9 7TF, UK
dQueen Elizabeth Hospital, Mindelsohn Way, Edgbaston, Birmingham B15 2GW, UK
eOdense University Hospital, J. B. Winsløws Vej 4, 5000 Odense C, Denmark
fRadboud University Nijmegen Medical Centre, Postbus 9101, 6500 HB Nijmegen, the Netherlands
gDepartment of Oncology, Aarhus University Hospital, Palle Juul-Jensens Boulevard 99, DK-8200 Aarhus N, Denmark
a r t i c l e i n f oArticle history:
Received 3 October 2019
Accepted 2 February 2020
Available online 4 February 2020
Keywords:
Rectal neoplasms
Radiotherapy
Clinical target volumes
Organ Preservationa b s t r a c t
With the introduction of population-based bowel cancer screening, rectal cancer is diagnosed at earlier
stages, yet standard treatment still requires the same extensive surgery that is used for more advanced
stages. Organ preserving treatment is rapidly developing and is subject of investigation in numerous clin-
ical trials. The STAR-TREC trial is an international, multi-centre randomised trial investigating organ
preservation using (chemo)radiotherapy. Patients with small mrT1-3bN0V0M0 tumours are randomized
between three arms: standard TME, organ preservation with SCRT or with CRT. In this trial, the clinical
target volume has been tailored to the early staged disease of the included patients. This mesorectal irra-
diation volume includes the mesorectum and pre-sacral lymph nodes at the level of the tumour, two cen-
timetres below and cranially up to the S2-3 interspace level. In contrast to conventional irradiation
volumes, the lateral lymph nodes and the nodes along the superior rectal artery are excluded. As a result,
the dose to the bowel, bladder, anal sphincter and the neurovascular plexus in the lower pelvis is sub-
stantially decreased, especially when combined with modern irradiation techniques, such as dynamic
arc therapy. These lower doses are expected to lead to decreasing acute and late toxicity and beneficial
functional outcomes. The implementation of this novel target volume will be accompanied by an exten-
sive quality assurance program in the STAR-TREC trial. We describe the rationale behind the novel,
mesorectal only radiotherapy treatment used in the STAR-TREC trial specifically tailored for early stage
disease, with the goal of organ preservation.
 2020 The Author(s). Published by Elsevier B.V. on behalf of European Society for Radiotherapy and
Oncology. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).1. IntroductionEarly stage rectal cancer has a favourable prognosis for patients
treated with total mesorectal excision (TME) [1]. Only 2% and 12%
of patients experience local or distant failure [2–4]. However,
resection of a low rectal tumour requires a permanent stoma in
approximately 40% of cases while many more patients will have
a temporary stoma [5–7]. Complications of surgical resection
include anastomotic leaks, autonomic nerve damage leading to uri-
nary incontinence or retention, sexual dysfunction and faecal
incontinence. Therefore, reconsidering TME as standard of care is
a high research priority. There is a need for less invasive and toxic
strategies, accompanied by good functional outcomes. In the last
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active surveillance of good responders after chemoradiotherapy
(CRT) [8–11].
The STAR-TREC trial explores whether primary short-course
radiotherapy (SCRT) or CRT followed by a two-stage response
assessment with selective use of local excision, is a safe alternative
to TME surgery (ClinicalTrials.gov Identifier: NCT02945566) [12].
Patients with small mrT1-3bN0V0M0 tumours are randomized
between three arms: standard TME, organ preservation (OP) with
SCRT or with CRT [12]. Patients in the OP arms with a complete
clinical response (cCR) enter active surveillance without further
treatment. For patients with a good partial response the residual
disease will be locally excised, while in poor responders a TME
resection is advocated.
In early stage tumours (C)RT can lead to OP in more than 50%
when combined with local excision [13–16]. Unfortunately, this
(C)RT can be accompanied by toxicity, morbidity and even mortal-
ity [14,15,17]. However, all available data on toxicity and mortal-
ity, are based on conventional radiotherapy techniques, with
large treatment volumes, including large elective LN regions. In
early stage rectal cancers, such as those included in the STAR-
TREC trial, a smaller tailored CTV is expected to be oncologically
safe. This paper describes the rationale for such a CTV and provides
delineation guidelines as used in the trial.2. Materials and methods
2.1. Participants
A working group (WG) of three experienced radiation oncolo-
gists (ROs), three junior ROs and a medical physicist reviewed cur-
rent literature and discussed the rationale of mesorectal
radiotherapy. All ROs were involved in design of the STAR-TREC
trial and experienced in rectal cancer treatment. The trials surgical
principal investigators were involved in defining the anatomical
boundaries of the clinical CTV. The WG focused on the definition
and delineation of the CTV; delineation of the gross tumour volume
(GTV) was beyond the scope of this project.
The open source software CERR [18] as well as Oncentra
Masterplan v4.1 (Elekta AB) were used to support the consensus
process and to facilitate the validation process by teleconference
discussions.
2.2. Consensus process
During a kick-off meeting, the WG defined a roadmap to
develop consensus guidelines on CTV delineation:
1. Review of available literature and pelvic anatomy.
2. Creation consensus CTV proposal.
3. Selection of two eligible cases with different tumour location
(mid-rectum and distal).
4. Delineation of first case by all ROs.
5. Discussion of results of first delineation.
6. Re-delineation of re-defined consensus by all ROs.
7. Discussion of results of second delineation.
8. Delineation of second case by all ROs.
9. Discussion of delineation of case 2 and validation of final
consensus guidelines.
10. Completion of delineation atlas.
3. Results
Patients eligible for participation in the STAR-TREC trial are
patients with small (<4 cm) mrT1-3bN0V0M0 tumours withoutinvolvement of the mesorectal fascia (MRF) or extra-mural vascu-
lar invasion (EMVI). The a priori risk of nodal involvement, espe-
cially outside the mesorectum, in these patients is substantially
lower than in patients with more advanced stages. The recom-
mended CTV for rectal cancer normally includes the GTV and elec-
tive nodal irradiation of the presacral space, mesorectum, internal
iliac nodes and if indicated, obturator nodes, external iliac nodes
and ischiorectal fossa [19]. Careful evaluation of the sites at risk
of nodal spread in the group eligible for inclusion can therefore
facilitate reduction of the CTV.
3.1. Sites of nodal involvement – mesorectum
Patients with low risk early rectal cancers do not undergo pre-
operative radiotherapy in most countries. Local control rate of 98%
after surgery in this group underlines that removal of only the
mesorectal envelope is sufficient in most patients [2–4]. Irradiating
only this mesorectal envelope should therefore also be sufficient.
In series evaluating LN distribution in resection specimens, it
has been shown that most nodal metastases are located peri-
tumoural in the mesorectum at the level of or a few centimetres
proximal of the tumour. Metastases distal from the tumour are
very rare. In an analysis of MRI and histopathological evaluation
of mesorectal LNs in 16 patients with T1-3 rectal cancer, 97% of
all 134 mesorectal LNs (benign and malignant) were located within
6 mm below and up to 5 cm proximal from the tumour [20]. None
of the malignant mesorectal LNs (n = 12) were located below the
tumour. Another study found 2 malignant LNs within 15 mm
below the tumour, but both patients had numerous LN metastases
at the level of the tumour [21]. Wang et al. found tumour deposits
up to 3 cm distal from the primary tumour in 4/62 patients, but
only in patients with stage III disease [22]. They demonstrated that
the outer circumferential area of the mesorectum was involved in
38,7% of all patients, underlining the importance of treating the
whole circumferential mesorectal tissue [23].
3.2. Sites of nodal involvement – common iliac and pre-sacral LNs
Recurrence pattern analyses have shown that in low and middle
rectal tumours without clinically node positive disease, the cranial
border can be lower than in conventional fields. Nijkamp et al.
showed that in the TME trial only one of 58 pN0 patients had a
recurrence just above the S2-3 interspace plane [24]. Syk et al.
found no recurrences above the level of S1-2 [25]. Lowering the
cranial border in low and middle rectal cancer without nodal dis-
ease has recently been implemented in the conventional CTV
[19] and is certainly indicated in the primary organ preservation
population.
3.3. Sites of nodal involvement – lateral LNs
In literature, varying definitions are used including only the
obturator LNs, the internal iliac nodes or the combination. The
recent delineation guideline by Valentini et al. defines the lateral
LN region as the triangular lympho-vascular area located between
the pelvic wall and the mesorectum, containing the lymphatic ves-
sels and the nodes along the internal iliac and obturator vessels [19].
Roels et al. [26] reported a rate of lateral LN involvement (defined as
LN along the middle rectal, the obturator, and the internal iliac ves-
sels) of 5% in T1-2 tumours and 14% in T3 tumours. The overall rate
was higher in patientswith nodal involvement in othermore preva-
lent areas. Socha et al. investigated the rate of lateral lymph node
metastasis in pT2 tumours treated with resection only. They found
a rate of 8.2% in distal tumours, located below the peritoneal fold,
and 0% in tumours above the peritoneal fold [27]. It is, however,
unclear what the clinical staging of these patients was. The rate is
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lymph node metastases, when present, clearly do not always result
in disease recurrence, since the rate of lateral recurrences in T2
tumours with TME resection alone is very low, see below.
Vuong et al. reported on ~500 patients with T2-3 tumours with
threatened circumferential margin, treated with brachytherapy,
followed by TME [28]. Unfortunately, the group was inhomoge-
neous, since node positive patients received post-operative CRT
and an unknown number of patients received adjuvant chemother-Fig 1. (a and b) Superior limit
Fig 2. (a and b) Inferior limit mapy. Still, treating only a limited amount of mesorectal tissue
directly around the tumour resulted in a low combined luminal
and nodal recurrence rate of 4.8%.
3.4. Local recurrences after TME surgery
Analysis of local recurrence pattern in patients from the TME
trial, including patients with LARC, showed lateral recurrences in
1,9% (n = 23) of the non-irradiated patients [29]. Of those, 18 hadmesorectal target volume.
esorectal target volume.
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involved CRM after surgery. In 996 patients without risk factors,
only 5 patients (0,5%) developed lateral recurrence. Analysis of
934 non-irradiated patients undergoing TME, only 3 (0,3%) devel-
oped a recurrence in a lateral LN [25]. These data indicate that in
early staged cT1-3bN0 patients the lateral LN region is not at risk.
A consistent finding is that the pre-sacral region is at consider-
able risk for local recurrence in all stages and tumour locations and
should always be included in the radiation fields [24–26,29].Fig 3. (a–c) Anterior limit m3.5. Local recurrences after TEM surgery
In a series of 100 patients treated for low risk pT1 tumours, 14
local recurrences were reported [30]. All were intraluminal and
11/14 could be attributed to local tumour regrowth. Concomitant
nodal involvement was present in 4/11 operated recurrences. In
144 patients with cT1-cT3, 44 local recurrences occurred [31].
After salvage surgery, histology showed that 24/26 recurrences
were endoluminal.esorectal target volume.
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endoluminal, rarely accompanied by mesorectal nodal disease.
Metastases in obturator or iliac lymph nodes were not reported.
Therefore, extending the radiotherapy fields beyond the mesorec-
tal fat seems unnecessary in this selected patient group.
In summary, there is adequate evidence in the literature that
conventional clinical CTV are not required in small cT1-3bN0
tumours, and a smaller CTV can be treated, including only the
mesorectum and pre-sacral region at the level of the tumour and
a few centimetres caudally and cranially to the level of the S2-3
interspace.
4. Mesorectal delineation guidelines
4.1. GTV
Only the macroscopic primary tumour is delineated. It is
strongly recommended that MRI images are available during
delineation.
4.2. CTV
The CTV includes the mesorectum considered at risk for LN
involvement and the pre-sacral LN at the same level. MRI should
be used to aid. Since all tumours should be amenable for local exci-
sion, proximal anterior located tumours (above peritoneal fold)
and distal tumours with extension in the anal canal are not eligible
for inclusion in the STAR-TREC trial. The delineation guidelines are,
therefore, not applicable for these locations.
On each slice, the mesorectum is delineated circumferentially:
4.2.1. Superior limit
 S2/S3 interspace (determined on the sagittal view). A horizontal
line from the anterior edge of the S2/3 interspace (Fig. 1a).
 A minimum of 2 cm is required from the superior limit of the
GTV to the CTV. In proximal tumours, this may require an
extension above the S2/3 interspace (Fig. 1b).
4.2.2. Inferior limit
 Two cm inferiorto the GTV (Fig. 2a).
In low tumours, where a 2 cm margin extends into the anal
canal, this margin is reduced to 1 cm, ie. a maximum of 1 cm
of the upper anal canal is delineated (Fig. 2b).
4.2.3. Anterior limit
 The MRF is contoured (Fig. 3a).Fig 4. (a–c) Posterior limit m If the MRF disappears anteriorly, the anterior border is the ante-
rior rectal wall (Fig. 3b).
 For cranial slices with no visible rectum, the anterior border is
defined by the contour used for the last cranial slice with visible
rectum (Fig. 3c).
4.2.4. Posterior limit
The anterior margin of the sacrum or coccyx, or the inner border
of the puborectalis muscle in caudal slices, to include the pre-
sacral LN (Fig. 4a-c).
4.2.5. Lateral limit
 The MRF is contoured.
 High pelvis – If the MRF disappears laterally, the inner border of
the pyriformis muscle is contoured (Fig. 5a).
 Mid pelvis – The MRF (Fig. 5b).
 Low pelvis – The inner border of the puborectalis muscle as it
converges to form the anorectal ring (Fig. 5c). When including
the anal canal, only the inner sphincter is delineated, the levator
ani and external sphincters are excluded (Fig. 5d).
4.3. PTV
Required PTV margins are highly dependable of local tech-
niques, such as positioning and position verification. A strict
instruction is, therefore, not in place. Within the STAR-TREC trial
we recommend supine positioning and daily online position verifi-
cation. In that case, a PTV margin of at least 1.5 cm anteriorly and
1 cm in all other directions should be used (according to local
experience, a smaller PTV margin in the direction of the sacrum
can be considered). If less than daily online position verification
is used or, for example, the patient is in prone position without
belly board, appropriate extra PTV margin should be added.5. Discussion
With introduction of population-based screening for bowel can-
cer, incidence of early staged rectal cancer has risen substantially.
Organ preservation in these early tumours warrants rethinking of
conventional radiotherapy CTVs, since these patients have excel-
lent overall survival rates, making long-term functional outcome
even more important. There are no current guidelines for this
specific patient category [19]. We describe the rationale for a
mesorectal only CTV specifically aiming at OP in early staged dis-
ease, i.e. patients with small (<4 cm) cT1-3bN0M0 tumours with-
out EMVI or involvement of the MRF. Irradiation of this CTV isesorectal target volume.
Fig 5. (a–d) Lateral limit mesorectal target volume.
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accompanied by an extensive quality assurance program [12].
The mesorectal CTV includes the mesorectum and pre-sacral
lymph nodes at the level of the tumour, 2 cm below and cranially
up to the S2-3 interspace level. The lateral LNs and the nodes along
the superior rectal artery (SRA) are excluded, in contrast to conven-
tional CTV.
The proposed CTV is largely corresponding with the recently
proposed volumes by Socha et al. [27]. In this systematic review
and meta-analysis the authors investigated the extent of extentof distal mesorectal (DMS) and distal intramural spread (DIS), the
risk of lateral lymph node (LLN) metastases in pT2 tumours, and
regional recurrence pattern after organ preservation, in order to
propose an adapted CTV for pT2 rectal cancer. The only discrep-
ancy between the two papers is the inclusion of the lateral lymph
node region. Based on a lymph node metastasis rate in the lateral
lymph nodes (internal iliac and obturator nodes) of 8.2% in
tumours below the peritoneal fold, they advise to include the
LLN in distal tumours. We advise not to include the LLN in cT1-
3N0 tumours, based on the very low recurrence rate (<1%) in the
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of multiple causes. First of all, the rate found by Socha is based
on surgical series of patients treated with resection with lateral
lymph adenectomywithout neo-adjuvant treatment. They selected
the pT2 patients, which does not encompass the same selection as
cT1-3bN0MRF- EMVI- patients for whomwe propose this CTV. The
pT2 patient group will probably also include patients with cN+ sta-
tus and other adverse features, such as EMVI. Secondly, it is possi-
ble that not all tumour cells that can be found in lymph nodes will
always develop into recurrence if left untreated, for example due to
immunological phenomena. Any risks of excluding the LLN region
will become clear from the STAR-TREC data.
The differences between the resection volume with TME resec-
tion, conventional CTV based on the Valentini guideline, the CTV
described in this paper and the Socha CTV are shown in Table 1.
5.1. Expected benefits for toxicity
Small bowel dosages are known to be associated with acute and
late bowel toxicity in conventional radiotherapy [32,33], although
this might be less pronounced with advanced radiation techniques
[34].
Mesorectum only radiotherapy results in 58% smaller CTVs
when compared to conventional CTVs [35], mainly cranially and
anteriorly, ensuring smaller volumes of irradiated small bowel
and probably less acute and late toxicity.
In addition, this smaller volume will decrease the dose to uro-
genital structures such as ureters, bladder and neurovascular
plexus. Lower doses to bladder, bladder trigone, vagina and
lumbo-sacral plexus have been shown to be associated with better
functional and HRQOL outcomes in gynaecological cancer patients
[36]. For rectal cancer, there is little data available. Analysis of the
toxicity data in the STAR-TREC study population will provide this
valuable information.
5.2. Possible risks of mesorectal target volume
The described mesorectal CTV is mainly based on expert opin-
ion and review of the limited available literature. Since the intro-
duction of this CTV within the trial is guided by standardised QA
and meticulous follow-up of patients, reliable data regarding pat-
terns of pelvic failure will become available. Use of a mesorectal
CTV outside trial setting is not recommended until the STAR-
TREC data will be available.
The theoretical risk of this substantially smaller irradiated vol-
ume is that it may result in an increase of recurrences in the lateral
LNs or nodes along the SRA, although this is not supported by data
from literature.
Literature on recurrences after a wait and see policy with stan-
dard chemoradiotherapy has shown that salvage TME resection is
possible and leads to good results [8]. Currently it is unclear
whether reduced treatment volumes will influence these resultsTable 1
Anatomic subsites included in CTV or resection volume for cT1-3bN0 rectal cancer.
TME resection Vale
Mesorectum + +
Presacral Nodes, pelvic – +
LLN post. = internal iliac LN – +
LLN ant. = obturator LN – –
Sphincter Complex – –
External Iliac Nodes – –
Ischiorectal Fossa – –
Inguinal Nodes – –
Presacral Nodes, abdominal – –
TME: total mesorectal excision, LLN: lateral lymph nodes, LN: lymph nodes.negatively, but given that most recurrences occur intraluminally,
this would seem unlikely. The STAR-TREC trial results are expected
to answer these questions.5.3. Quality assurance (QA) program
Any new treatment would benefit from a QA program, to ensure
correct and reproducible implementation over different centres.
Reproducibility of delineation is important to ensure homogeneity
of delineations within trials, but also to ensure consistent daily
clinical practice. Only then clinical outcomes and toxicity can be
compared. Quality of delineation is even more important when
using modern irradiation techniques, such as dynamic arc therapy,
because of the conformality of the high dose volume [37].
To ensure correct and consistent implementation of this novel
mesorectal only CTV in all participating centres of the STAR-TREC
trial, an extensive program with pre-trial workshops and direct
feedback after patient inclusion has been set up.6. Conclusions
The STAR TREC trial facilitates the controlled introduction of a
novel CTV for good prognosis, early rectal cancer. This will enable
the collection of high-quality data on treatment toxicity and organ
preservation efficacy. Treatment of this novel target volume should
preferably be combined with modern (IMRT/VMAT) treatment
techniques for optimal normal tissue sparing. Recurrence patterns
from the trial will inform us on the safety of this mesorectal CTV
and ultimately, facilitate further treatment refinement to achieve
optimum oncological efficacy with the lowest toxicity and best
functional outcomes for our early rectal cancer patients.Funding source
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